FDA grants regular approval and expands indication for Padcev for patients with locally advanced or metastatic urothelial cancer
Seagen Inc. and Astellas Pharma Inc. announced the FDA granted Padcev (enfortumab vedotin-ejfv) regular approval in the U.S., in addition to approving a new indication for adult patients… read more.
